
All About Nicotinamide Riboside
Every year, Americans spend billions of dollars on anti-aging products.
While most anti-aging products are used to reverse signs of aging on your skin, nicotinamide riboside is promoted to reverse signs of aging from inside your body.
Within your body, nicotinamide riboside is converted into NAD+, a helper molecule that's made throughout your body and supports many aspects of healthy aging.
This article explains everything you need to know about nicotinamide riboside, including its benefits, side effects and dosage.
What is nicotinamide riboside?
Nicotinamide riboside is a form of vitamin B3, also called niacin.
Like other forms of vitamin B3, nicotinamide riboside is converted by your body into nicotinamide adenine dinucleotide (NAD+), a coenzyme or helper molecule.
NAD+ helps to promote many key biological processes, such as:
converting food into energy
repairing damaged DNA
fortifying cells' defense systems
setting your body's internal clock or circadian rhythm
However, the amount of NAD+ in your body naturally falls with age.
Low NAD+ levels have been linked to health concerns like aging and chronic illnesses, such as heart disease, Alzheimer's disease, and vision loss.
Nicotinamide riboside supplements have quickly become popular because they appear to be effective at raising NAD+ levels.
Nicotinamide riboside is also found in trace amounts in cows' milk, yeast and beer.
Potential benefits
Here are some potential health benefits of nicotinamide riboside.
Easily converted into NAD+
NAD+ is a coenzyme, or helper molecule, that takes part in many biological reactions.
While it's essential for optimal health, research shows that NAD+ levels continue to fall with age. Low NAD+ levels are linked to a variety of harmful diseases.
One way to raise NAD+ levels is to take in NAD+ precursors — the building blocks of NAD+ — such as nicotinamide riboside.
Animal and human studies show that nicotinamide riboside efficiently and consistently raises blood NAD+ levels. What's more, it's more readily converted by your body than other NAD+ precursors.
Activates enzymes that may promote healthy aging
Nicotinamide riboside helps increase NAD+ levels in your body.
In response, NAD+ activates certain enzymes that may promote healthy aging.
One group is sirtuins, which appear to improve lifespan and overall health in animals. Studies indicate that sirtuins may repair damaged DNA, reduce inflammation and offer other benefits that promote healthy aging.
May help protect brain cells
NAD+ plays a key role in helping your brain cells age well.
Within brain cells, NAD+ helps control the production of PGC-1-alpha, a protein that appears to help protect cells against oxidative stress.
Researchers believe that oxidative stress is linked to age-related brain disorders such as Alzheimer's and Parkinson's disease.
However, it's still unclear how helpful raising NAD+ levels is in people with age-related brain disorders. More human studies are needed.
May lower heart disease risk
Aging is a major risk factor for heart disease, which is the world's leading cause of death. It can cause blood vessels to become thicker, stiffer, and less flexible.
Such changes can raise blood pressure levels and make your heart work harder.
Research shows that nicotinamide riboside may help raise NAD+ levels, helped reduce blood vessel stiffness, and reduce the chance of high blood pressure.
That said, more human research is needed.
Potential risks and side effects
Nicotinamide riboside is likely safe with few — if any — side effects.
In human studies, taking 1,000 mg per day had no harmful effects.
However, most human studies are short in duration and have very few participants. For a more accurate idea of its safety, more robust human studies are needed.
Some people have reported mild to moderate side effects, such as nausea, fatigue, headaches, diarrhea, stomach discomfort and indigestion.
Dosage and recommendations
Nicotinamide riboside is available in tablet or capsule form under its own name or with the brand name Niagen.
It is available at select health-food stores and online retailers.
Nicotinamide riboside supplements typically contain just nicotinamide riboside, but some manufacturers combine it with other ingredients like Pterostilbene, which is a polyphenol — an antioxidant that is chemically similar to resveratrol.
Most nicotinamide riboside supplement brands recommend taking 250–300 mg per day, the equivalent of 1–2 capsules per day depending on the brand.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

USA Today
33 minutes ago
- USA Today
Medical debt remains on credit reports after Biden-era rule tossed by judge
Consumers were dealt a blow after a federal judge in Texas tossed out a Biden-era rule that would have banned the inclusion of medical debt on credit reports. In a move that advocates told USA TODAY eliminates a vital consumer protection, U.S. District Judge Sean Jordan on July 11 granted a request from President Donald Trump's administration and two financial industry groups to vacate the medical debt rule. The medical debt rule, finalized in January before former President Joe Biden left office, would've banned medical debt on credit reports and prohibited lenders from using a person's medical debt history to make lending decisions. The rule was scheduled to take effect in March, but the two trade groups sued the Consumer Financial Protection Bureau to halt the rule, and Jordan issued a stay, delaying the rule's start date. In late April, the Trump-appointed CFPB leadership opted not to oppose the lawsuit and filed a joint motion with the financial industry groups – the Consumer Data Industry Association and Cornerstone Credit Union League – to ask the judge to vacate the medical debt rule. Jordan, appointed during Trump's first administration, agreed with the trade groups that it was "fair, adequate and reasonable" to vacate the medical debt rule because it exceeded the CFPB's authority under the Fair Credit Reporting Act. Medical debt 'will likely get worse' Patricia Kelmar, senior director of health care campaigns at the U.S. PIRG Education Fund, said rule was necessary due to protect consumers from medical debt errors on credit reports. Medical bills accounted for more than half of debt collection on consumers' credit records, according to a 2022 report from the CFPB. "The problem is still here and will likely get worse," Kelmar said. "Medical debt on credit reports is disputed nearly three times as frequently as credit card debt." She said many of the 15 million Americans with medical debt on their credit reports are "penalized with lower credit scores, not because they owe the bill, but because they are still fighting it, or the hospitals reported it wrong." But industry groups cheered the decision. The medical debt rule would've potentially dealt lenders an "inaccurate and incomplete picture when making lending decisions," Dan Smith, president and CEO of the Consumer Data Industry Association, said in a statement. "Information about unpaid medical debts is an important element in assessing a consumer's ability to pay," Smith said. "This is the right outcome for protecting the integrity of the system." Paid medical debts, unpaid medical debts less than a year old and medical debts less than $500 already have been removed from credit reports by the three largest credit reporting companies. However, with the medical debt rule scrubbed, consumers can still expect larger medical debts to appear on credit reports. The decision comes as the Trump's sweeping tax cut and spending law could jeopardize health insurance coverage for millions of Americans in the coming years. The law would cut about $1 trillion from Medicaid and Affordable Care Act insurance plans, eliminating insurance coverage for 11.8 million people over the next decade, according to the nonpartisan Congressional Budget Office. Another 5 million could lose health insurance because the law doesn't extend Biden's COVID-19 pandemic-era tax credits that made ACA plans cheaper for consumers, according to a previous CBO analysis.


Medscape
41 minutes ago
- Medscape
Emerging Options in Second-Line Therapy for Metastatic NSCLC
Standard treatment of metastatic non-small cell lung cancer (NSCLC) is immunotherapy in the first line, followed by combination therapy with docetaxel and ramucirumab in the second line. But a new antibody-drug conjugate (ADC) and other drugs currently in development are broadening the options for these patients. Dr Tom Stinchcombe of Duke University in Durham, North Carolina, discusses ADCs, checkpoint inhibitors combined with tumor treating fields (TTF) therapy, and other targeted therapies being evaluated as second-ling therapies for metastatic NSCLC. Dr Stinchcombe first describes telisotuzumab vedotin, a c-Met-directed antibody and microtubule inhibitor conjugate indicated for metastatic NSCLC patients with high c-Met protein overexpression. The drug received FDA-accelerated approval on the basis of the LUMINOSITY trial, in which telisotuzumab vedotin monotherapy provided clinically meaningful response and progression-free survival in this population. He then describes TTF therapy, which delivers electrical impulses to the tumor site to disrupt processes critical for cancer cell division. The LUNAR trial showed the benefit of TTF plus checkpoint inhibition in second-line treatment of metastatic NSCLC, suggesting an additive benefit of this combination. Finally, he discussed two trials showing second-line therapies for patients with KRAS G12C mutations, in which sotorasib and adagrasib have shown potential benefit over docetaxel in this population.
Yahoo
42 minutes ago
- Yahoo
WeightWatchers Returns With a Plan for the New GLP-1 World
WeightWatchers is no longer content to stew about its seemingly slender prospects in the Wegovy era. After the GLP-1 onslaught plunged the company into Chapter 11 submission in May, the dieting brand emerged from bankruptcy last week to announce it had successfully trimmed the fat from its considerable debt load, built a strategy for success moving forward, and plans to relist on the Nasdaq. READ ALSO: Bitcoin Tops $120,000 With Congress Poised to Consider Key Crypto Bills and Inflation Data and Bank Earnings Kick Off a Crucial Test for Markets It's worth remembering that the company, which rebranded as WW International in 2019, was already in trouble before a little weekly injectable came along that promised the same results as being a WeightWatchers client without the arduous processes of carefully scheduled workout classes and calorie-counted meals. The pandemic had already crushed its in-person business, and business never recovered. In 2018, the company reported annual revenue of $1.5 billion; by 2021, that had fallen to $1.2 billion, and by 2024, a measly $800 million. By May, company lawyers proclaimed in a bankruptcy hearing that an 'evolution in consumer preferences and the rapid rise of GLP-1s' made it unable to service its $1.6 billion debt load. Now? WeightWatchers wants to turn GLP-1s from poison pill to bottom line miracle drug, among other plans to rev up new revenue: The company has struck a deal with Novo Nordisk to sell weight loss drug Wegovy directly to clients on its online platform at $299 per month. WeightWatchers set the stage for such a movie in 2023 when it acquired telehealth company Sequence for $132 million. The company also plans to push into menopause treatment plans, which it says is designed to address a broader gap in healthcare. 'It is a very natural overlap. In the perimenopausal and menopausal phase, up to 70% of women experience weight gain,' newly hired Chief Medical Officer Dr. Kim Boyd told Reuters last week. The Ringer: The company will also have help from someone who knows the GLP-1 industry with great intimacy. As it emerges from bankruptcy, WeightWatchers has appointed a new board of directors — among them former Eli Lilly president Mike Mason, who helped pioneer the GLP-1 industry. 'As medical treatments like GLP-1s become more widely used, the need for trusted, comprehensive care models that combine medication with lasting lifestyle change has never been greater,' Mason said in a statement. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data